TZLS-501

About Tiziana Life Sciences

Tiziana Life Sciences is a UK-based, Nasdaq-listed biotech focused on developing novel immunotherapies for neurodegenerative and neuroinflammatory diseases. Its core strategy leverages the intranasal delivery of foralumab, a fully human anti-CD3 monoclonal antibody, to achieve targeted CNS immunomodulation. The company has generated promising early clinical data in non-active Secondary Progressive Multiple Sclerosis and is rapidly expanding its clinical programs into Multiple System Atrophy, Alzheimer's, and ALS, supported by key collaborations with leading academic institutions like Brigham and Women's Hospital.

Therapeutic Areas